Balyasny Asset Management
CGON icon

Balyasny Asset Management’s CG Oncology CGON Stock Holding History

Balyasny Asset Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$959K Buy
+14,171
New +$803K ﹤0.01% 2096
2024
Q4 		– Sell
-153,814
Closed -$5.8M – 2799
2024
Q3 		$5.8M Buy
153,814
+115,852
+305% +$4.06M 0.01% 1194
2024
Q2 		$1.2M Buy
+37,962
New +$1.32M ﹤0.01% 1719

Other funds holding CGON

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management's CGON Position: Q1 2026 in Review

Balyasny Asset Management opened a new position in CG Oncology (CGON) in Q1 2026: 14,171 shares worth $959K. The stake represents ﹤0.01% of the portfolio and ranks #2096 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in CGON as recently as Q3 2024.

Balyasny Asset Management first reported a position in CGON in Q2 2024 and has held it in 3 quarters since. The position peaked at $5.8M in Q3 2024. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

  • Balyasny Asset Management held 14,171 shares of CG Oncology worth $959K as of Q1 2026.
  • CG Oncology was a new Balyasny Asset Management position in Q1 2026.
  • CG Oncology made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2096 holding.
  • Balyasny Asset Management first reported a position in CG Oncology in Q2 2024 and has held it in 3 quarters since.
  • Balyasny Asset Management's CG Oncology position peaked at $5.8M in Q3 2024.
  • 233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.